Geode Capital Management LLC Buys Shares of 48,639 Bicara Therapeutics Inc. (NASDAQ:BCAX)

Geode Capital Management LLC acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 48,639 shares of the company's stock, valued at approximately $1,239,000. Geode Capital Management LLC owned about 0.09% of Bicara Therapeutics at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of BCAX. Barclays PLC purchased a new stake in Bicara Therapeutics in the third quarter worth $255,000. Jane Street Group LLC purchased a new stake in shares of Bicara Therapeutics in the third quarter worth $309,000. Wellington Management Group LLP bought a new position in shares of Bicara Therapeutics in the third quarter worth approximately $19,458,000. Soros Fund Management LLC bought a new stake in shares of Bicara Therapeutics in the 3rd quarter worth $509,000. Finally, Samsara BioCapital LLC purchased a new position in shares of Bicara Therapeutics during the third quarter valued at approximately $891,000.

Bicara Therapeutics Trading Down 5.7 %

BCAX traded down $0.87 during trading on Friday, hitting $14.38. The company's stock had a trading volume of 556,465 shares, compared to its average volume of 403,544. Bicara Therapeutics Inc. has a twelve month low of $14.13 and a twelve month high of $28.09. The business's fifty day moving average price is $19.47.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). Equities research analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BCAX. Cantor Fitzgerald assumed coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set an "overweight" rating for the company. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a "strong-buy" rating in a research note on Tuesday, November 5th. TD Cowen assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a "buy" rating on the stock. Rodman & Renshaw started coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They set a "buy" rating and a $48.00 price objective on the stock. Finally, Morgan Stanley started coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $43.00.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.